Eiichi Tokuda

Dr. Eiichi Tokuda

Nihon University
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Neuron
Verified
Journal Article
Closed access
TITaro Ishiguro
Taro Ishiguro
NSNozomu Sato
Nozomu Sato
MUMorio Ueyama
Morio Ueyama
NFNobuhiro Fujikake
Nobuhiro Fujikake
CSChantal Sellier
Chantal Sellier
KIKinya Ishikawa
Kinya Ishikawa

1 June 2013 in Neurobiology of Disease
Verified
Journal Article
Closed access
Eiichi TokudaEiichi Tokuda
Eiichi Tokuda
EOEriko Okawa
Eriko Okawa
SWShunsuke Watanabe
Shunsuke Watanabe
SOShin-Ichi Ono
Shin-Ichi Ono
SMStefan L. Marklund
Stefan L. Marklund

19 November 2019 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
Eiichi TokudaEiichi Tokuda
Eiichi Tokuda
YTYo-Ichi Takei
Yo-Ichi Takei
SOShinji Ohara
Shinji Ohara
NFNoriko Fujiwara
Noriko Fujiwara
Isao HozumiIsao Hozumi
Isao Hozumi
YFYoshiaki Furukawa
Yoshiaki Furukawa
Background: A subset of familial forms of amyotrophic lateral sclerosis (ALS) are caused by mutations in the gene coding Cu/Zn-superoxide dismutase (SOD1). Mutant SOD1 proteins are susceptible to misfolding and abnormally accumulated in spinal cord, which is most severely affected in ALS. It, however, remains quite controversial whether misfolding of wild-type SOD1 is involved in more prevalent sporadic ALS (sALS) cases withoutSOD1mutations.Methods: Cerebrospinal fluid (CSF) from patients including sALS as well as several other neurodegenerative diseases and non-neurodegenerative diseases was examined with an immunoprecipitation assay and a sandwich ELISA using antibodies specifically recognizing misfolded SOD1.Results: We found that wild-type SOD1 was misfolded in CSF from all sALS cases examined in this study. The misfolded SOD1 was also detected in CSF from a subset of Parkinson’s disease and progressive supranuclear palsy, albeit with smaller amounts than those in sALS. Furthermore, the CSF samples containing the misfolded SOD1 exhibited significant toxicity toward motor neuron-like NSC-34 cells, which was ameliorated by removal of the misfolded wild-type SOD1 with immunoprecipitation.Conclusions: Taken together, we propose that misfolding of wild-type SOD1 in CSF is a common pathological process of ALS cases regardless ofSOD1mutations.

Verified
Journal Article
Open access
PDF file
Eiichi TokudaEiichi Tokuda
Eiichi Tokuda
YFYoshiaki Furukawa
Yoshiaki Furukawa
Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disease affecting both upper and lower motor neurons, and currently, there is no cure or effective treatment. Mutations in a gene encoding a ubiquitous antioxidant enzyme, Cu,Zn-superoxide dismutase (SOD1), have been first identified as a cause of familial forms of ALS. It is widely accepted that mutant SOD1 proteins cause the disease through a gain in toxicity but not through a loss of its physiological function. SOD1 is a major copper-binding protein and regulates copper homeostasis in the cell; therefore, a toxicity of mutant SOD1 could arise from the disruption of copper homeostasis. In this review, we will briefly review recent studies implying roles of copper homeostasis in the pathogenesis of SOD1-ALS and highlight the therapeutic interventions focusing on pharmacological as well as genetic regulations of copper homeostasis to modify the pathological process in SOD1-ALS.

1 January 2007 in Toxicology
Verified
Journal Article
Closed access
Eiichi TokudaEiichi Tokuda
Eiichi Tokuda
SOShin-Ichi Ono
Shin-Ichi Ono
KIKumiko Ishige
Kumiko Ishige
ANAkira Naganuma
Akira Naganuma
YIYoshihisa Ito
Yoshihisa Ito
TSTakashi Suzuki
Takashi Suzuki

14 September 2009 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
Eiichi TokudaEiichi Tokuda
Eiichi Tokuda
EOEriko Okawa
Eriko Okawa
SOShin‐Ichi Ono
Shin‐Ichi Ono